FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Kinetics topics
Medical Device
Polypeptide
Nucleic Acid
Nucleic Acids
Specificity
Surfactant
Enhancement
Scattering
Electrolyte
Conductive Elements
Amplification
Red Blood Cell
Red Blood Cells
Antibodies
Luciferase

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Kinetics patents



      
           
This page is updated frequently with new Kinetics-related patent applications. Subscribe to the Kinetics RSS feed to automatically get the update: related Kinetics RSS feeds. RSS updates for this page: Kinetics RSS RSS


Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies

Mesoporous nanocrystalline film architecture for capacitive storage devices

Date/App# patent app List of recent Kinetics-related patents
10/09/14
20140302999
 Method for determination of pharmacological properties of recombinant proteins patent thumbnailMethod for determination of pharmacological properties of recombinant proteins
The present invention is directed to a method for obtaining an in vitro pharmacological model of a recombinant protein drug in a given host. A plurality of biomolecules are selected which are known or suspected to influence pharmacology of the recombinant protein in the host via a binding interaction with the recombinant protein.
10/09/14
20140302612
 Nematic liquid crystal thin films for chemical vapor sensing patent thumbnailNematic liquid crystal thin films for chemical vapor sensing
A method of detecting an analyte by: providing a device having a substrate, an alignment layer on the substrate, and a film having 4-pentyl-4′-cyanobiphenyl on the alignment layer; exposing the film to air suspected of containing the analyte; measuring a change in a physical property of the film in response to exposing the film; measuring the kinetics of the change in the physical property; and correlating the kinetics to the concentration of the analyte, identification of the analyte, or both.. .
10/09/14
20140302144
 Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies patent thumbnailMulti-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies
The invention relates to a pharmaceutical formulation for sustained delivery of a therapeutic agent, preferably a protein, polypeptide, an antibody or an antibody fragment, comprising one or more gel forming peptides wherein the formulation exhibits sustained delivery for at least two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks or more. In one embodiment, the invention relates to a formulation comprising self-assembling peptides that undergo sol-gel transition in the presence of an electrolyte solution such as biological fluids and salts.
10/09/14
20140301020
 Mesoporous nanocrystalline film architecture for capacitive storage devices patent thumbnailMesoporous nanocrystalline film architecture for capacitive storage devices
A mesoporous, nanocrystalline, metal oxide construct particularly suited for capacitive energy storage that has an architecture with short diffusion path lengths and large surface areas and a method for production are provided. Energy density is substantially increased without compromising the capacitive charge storage kinetics and electrode demonstrates long term cycling stability.
10/09/14
20140298996
 Sorbents for carbon dioxide reduction from indoor air patent thumbnailSorbents for carbon dioxide reduction from indoor air
A sorbent for c02 reduction from indoor air from an enclosed space. In some embodiments, the sorbent comprises a solid support and an amine-based compound being supported by the support.
10/02/14
20140296199
 Pharmaceutical delivery systems for hydrophobic drugs and compositions compositions comprising same patent thumbnailPharmaceutical delivery systems for hydrophobic drugs and compositions compositions comprising same
A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
10/02/14
20140295569
 Reagent for detection and assessment of free chlorine in aqueous solution patent thumbnailReagent for detection and assessment of free chlorine in aqueous solution
Provided is a heat dried reagent composition that is dry, methods of making it, and methods of using it. The heat dried reagent composition can be characterized by one or more of stability to the heat drying conditions; storage stability of the heat dried reagent composition; fast rehydration time; rapid assay kinetics; and assay precision.
10/02/14
20140295568
 Reagent for detection and assessment of total chlorine in aqueous solution patent thumbnailReagent for detection and assessment of total chlorine in aqueous solution
Provided is a heat dried reagent composition that is dry, methods of making it, and methods of using it. The heat dried reagent composition can be characterized by one or more of: stability to the heat drying conditions; storage stability of the heat dried reagent composition; fast rehydration time; rapid assay kinetics; and assay precision.
10/02/14
20140295094
 Combustion deposition systems and methods of use patent thumbnailCombustion deposition systems and methods of use
Combustion deposition systems and methods of using combustion deposition systems are disclosed. In an embodiment, a combustion deposition system may include a burner that is in fluid communication with at least one supply of at least one precursor such that the at least one precursor can be introduced to a flame output from the burner, at least one electrode positioned at least proximate to the flame, and a voltage source operably coupled to the at least one electrode.
09/25/14
20140288317
 Aryloxyanilide imaging agents patent thumbnailAryloxyanilide imaging agents
The present invention provides a novel radiolabelled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging.
09/25/14
20140288036
Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
Described are steroidal c-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β-ol or analogs thereof with tributylstannyl diazines.
09/18/14
20140275493
Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
Antibodies are disclosed that bind to and inhibit the anti-coagulant function of tfpi and have a lower affinity for tfpi at ph 6.0 than at ph 7.4. The lower affinity at ph 6 improves circulating half-life (t½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded.
09/18/14
20140274983
Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
Prodrugs of steroidal c-17 benzoazoles, pyrimidinoazoles (az-abenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at a ring portion of the abc ring structure of the steroid.
09/18/14
20140273044
Method for replacing biomarkers of protein kinetics from tissue samples by biomarkers of protein kinetics from body fluids after isotopic labeling in vivo
Provided herein are method for measuring the rate of synthesis, breakdown, transport, or other kinetic parameters of a protein in a tissue of medical interest, without requiring physical sampling of the tissue, by a measurement of the protein in a body fluid. Methods may include selecting one or more target proteins in a tissue; administering an isotope-labeled molecule to a subject for a period of time sufficient for said isotope-labeled molecule to enter into and label the one or more target proteins to produce one or more isotope-labeled target proteins; collecting a volume of a body fluid, wherein the volume comprises one or more isotope-labeled target proteins that escaped or were released from the tissue; enriching or isolating the one or more isotope-labeled target proteins from the volume; performing a mass spectrometric measurement of the isotopic content, rate of incorporation, and/or pattern or rate of change in isotopic content and/or pattern of isotope labeling of the one or more enriched or isolated isotope-labeled target proteins; and calculating at least one kinetic parameter of the one or more enriched or isolated isotope-labeled target proteins, where the kinetic parameter of the one or more isotope-labeled target proteins from the volume of a body fluid reflects the corresponding kinetic parameter of the one or more target proteins in the tissue; and inferring the at least one kinetic parameter of the one or more target proteins in the tissue based on the corresponding at least one kinetic parameter of the one or more target proteins in the body fluid..
09/18/14
20140271872
Drug delivery system
Disclosed herein are novel methods of treating diseases, novel dosage forms, and novel methods of modulating the pharmacokinetics of active ingredients.. .
09/18/14
20140266194
Method and apparatus for measuring physico-chemical properties using a nuclear magnetic resonance spectrometer
Methods for measuring physico-chemical properties using a nuclear magnetic resonance spectrometer are disclosed, including methods to determine an initial amount of a substance, usually a liquid, contained inside a porous material and an initial amount of the substance, usually a liquid, present outside the porous material, methods to measure the release kinetics of a substance, such as a liquid, from a porous material, and methods for performing chemical reactions and other physico-chemical operations in situ inside a nuclear magnetic resonance probe after a sample is loaded into a nuclear magnetic resonance spectrometer. The apparatuses for performing these methods are also disclosed..
09/11/14
20140255939
Nucleic acid-based linkers for detecting and measuring interactions
The invention provides compositions comprising nucleic acid complexes for use in monitoring binding interactions and in measuring association and/or dissociation kinetics with or without force, detecting analytes, screening aptamers, and encoding/encrypting information. In some instances, the nucleic acid complexes are double-stranded nicked nucleic acids comprising a scaffold nucleic acid hybridized to one or more oligonucleotides.
09/04/14
20140249413
Theranosis of macrophage-associated diseases with ultrasmall superparamagnetic iron oxide nanoparticles (uspio)
Macrophages sequester and aggregate ultrasmall superparamagnetic iron oxide nanoparticles (uspio) in their lysosomes. The amount of uspio loading of macrophages depends upon the route and dose of administration, and the pharmacokinetics of accumulation and removal.
09/04/14
20140249297
Antibodies with modified isoelectric points
The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. Increased serum half-life in vivo..
09/04/14
20140249136
Parenteral formulations of dopamine agonists
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics..
09/04/14
20140249124
Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
09/04/14
20140248237
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
The invention relates to the discovery of novel soluble neutral active hyaluronidase glycoproteins (shasegps), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active shasegp domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
08/28/14
20140243340
Cytochrome p450 oxidase inhibitors and uses thereof
Or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of cyp enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by cyp enzymes..
08/28/14
20140243331
Inhibitors of inv(16) leukemia
This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (aml). The inv(16) fusion results in expression of the cbfβ-smmhc fusion protein in the blood cells of afflicted patients.
08/28/14
20140238265
Product
A method for manufacturing a cellular geopolymer product, which method comprises the steps: (a) forming an activated geopolymer premix by addition to a geopolymer premix of an activator compound that initiates a condensation reaction in the geopolymer premix; (b) casting the activated geopolymer premix in a desired configuration; and (c) generating gas bubbles in the activated geopolymer premix as the condensation reaction proceeds and the activated geopolymer premix stiffens to produce a self-supporting cellular structure; and (d) curing the self-supporting cellular structure to produce the cellular geopolymer product, wherein in step (c) the characteristics of the activated geopolymer premix and the reaction kinetics of the condensation reaction are controlled to achieve formation of the self-supporting cellular structure.. .
08/21/14
20140236069
Pharmacokinetics of iontophoretic sumatriptan administration
Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.. .
08/21/14
20140232029
Kit for measuring the thrombin generation in a sample of a patient's blood or plasma
The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and cacl2.
08/14/14
20140230080
Method for inducing hepatocellular variation, and production method for chimeric non-human animal having humanized liver
The present invention provides (1) a method for producing a non-human animal having a humanized liver, comprising transplanting human hepatic stem cells and/or hepatic progenitor cells and/or immature hepatocytes to a liver-damaged non-human animal to induce the differentiation of the cells into hepatocytes, (2) a non-human animal having a humanized liver, produced by the method, (3) a method for examining the pharmacokinetics and/or hepatotoxicity of a test substance, comprising using the animal, (4) a method for producing human hepatocytes, comprising transplanting human hepatic stem cells and/or hepatic progenitor cells and/or immature hepatocytes to a liver-damaged non-human animal to induce the differentiation of the cells into hepatocytes, and (5) a method for examining the pharmacokinetics and/or hepatotoxicity of a test substance, comprising using human hepatocytes produced by the method.. .
08/07/14
20140221434
Altering pharmacokinetics of pirfenidone therapy
The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) therapy.. .
08/07/14
20140221433
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
The present invention relates to an improved and shortened synthesis of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide and the mesylate monohydrate salt thereof by using boronic acid derivatives or borolane reagents while avoiding toxic organic tin compounds and to the mesylate monohydrate salt of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions.. .
07/24/14
20140205918
Storage element and method for the production thereof
A storage element for a solid electrolyte battery is provided. The storage element has a main member having a porous matrix of sintered ceramic particles in which particles that are made of a metal and/or a metal oxide and jointly form a redox couple are embedded.
07/24/14
20140205525
Amine promotion for co2 capture
Promoter amines are used to enhance co2 uptake by sterically hindered or tertiary amines. The promoter amines can be cyclic amines, including aromatic cyclic amines or bridged cyclic amines.
07/17/14
20140200547
Method for altering drug pharmacokinetics based on medical delivery platform
A method for directly delivering whereby a substance is introduced into an intradermal space within mammalian skin which involves administering the substance through at least one small gauge hollow needle having an outlet with an exposed height between 0 and 1 mm. The outlet is inserted into the skin to a depth of between 0.3 mm and 2 mm such that the delivery of the substance occurs at a depth between 0.3 mm and 2 mm..
07/10/14
20140193910
Methods for producing pancreatic precursor cells and uses thereof
The present invention is directed to methods for readily propagating somatic pancreatic precursor cells. The methods comprise isolating cells from intact pancreatic samples and enhancing guanine nucleotide (gnp) biosynthesis in cultures comprising these cells, thereby expanding guanine nucleotide pools.
07/10/14
20140193498
Compositions and methods for treating metabolic disorders
Compositions and methods for improving the pharmacokinetics and reducing the risk of adverse events resulting from biguanide compound administration are provided, comprising administering delayed release formulations of such compounds having a lag phase release.. .
07/10/14
20140193320
Use of triphenyl phosphate as risk mitigant for metal amide hydrogen storage materials
A process in a resulting product of the process in which a hydrogen storage metal amide is modified by a ball milling process using an additive of tpp. The resulting product provides for a hydrogen storage metal amide having a coating that renders the hydrogen storage metal amide resistant to air, ambient moisture, and liquid water while improving useful hydrogen storage and release kinetics..
07/10/14
20140192941
Method of acceleration of nuclear transmutation of isotopes by carrying out exothermic reactions
Methods for acceleration of nuclear transmutation of tritium and radioactive isotopes of metals, and decontamination of metals contaminated with radioactive isotopes by destroying radioactive isotopes to a required level of residual radioactive inventory in metals with simultaneous release of thermal energy via stimulating accelerated transmutation with the half-life parameters describing kinetics of radioactive isotope destruction much shorter than their generally accepted half-life. The stimulus is applied to radioactive metals by placing them into a chamber, exposing them to gaseous substances of the group of hydrogen, deuterium, tritium, or a mixture of these isotopes in a molecular hydrogen form for said gaseous substances to be absorbed by the metals, heating the metals to a temperature of at least 200° c.
07/03/14
20140187630
Novel compound and medical use thereof
Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2s)-2-amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for parkinson's disease and/or parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa..
07/03/14
20140183055
Electrochemically mediated atom transfer radical polymerization
Electrochemical reduction of an exemplary atrp catalyst, c11br2/me6tren, is shown to be an efficient process to mediate and execute an atrp. The onset of polymerization occurs only through passage of a cathodic current achieved under a reductive potential to form cu1br2/me6tren, within the reaction medium.
06/26/14
20140179739
Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
The invention relates to a method of treating attention deficit disorder (add) and attention deficit/hyperactivity disorder (adhd) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.. .
06/26/14
20140175054
Independent radiant gas preheating for precursor disassociation control and gas reaction kinetics in low temperature cvd systems
In one embodiment, a gas distribution assembly includes an injection block having at least one inlet to deliver a precursor gas to a plurality of plenums from at least two gas sources, a perforated plate bounding at least one side of each of the plurality of plenums, at least one radiant energy source positioned within each of the plurality of plenums to provide energy to the precursor gas from one or both of the at least two gas sources and flow an energized gas though openings in the perforated plate and into a chamber, and a variable power source coupled to each of the radiant energy sources positioned within each of the plurality of plenums.. .
06/19/14
20140171457
Implantable polymeric device for sustained release of buprenorphine
The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time.
06/19/14
20140171387
Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
Since a compound represented by formula (i) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc.
06/19/14
20140171370
Formulations of active agents for sustained release
The present invention provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs..
06/19/14
20140170048
Use of triammonium salt of aurin tricarboxylic acid as risk mitigant for aluminum hydride
A process and a resulting product by process of an aluminum hydride which is modified with by physically combining in a ball milling process an aluminum hydride with a triammonium salt of aurin tricarboxylic acid. The resulting product is an aluminum hydride which is resistant to air, ambient moisture, and liquid water while maintaining useful hydrogen storage and release kinetics..
06/19/14
20140166483
Electrokinetics-assisted sensor
An electrokinetics-assisted sensor for sensing a target material. The sensor may include a microstructure deflectable in response to added mass on its body.
06/12/14
20140163452
Pharmacokinetics of iontophoretic sumatriptan administration
Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.. .
06/12/14
20140163057
Implantable polymeric device for sustained release of buprenorphine
The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time.
06/12/14
20140162942
Inhibition of cyp3a drug metabolism
The present invention provides methods, pharmaceutical compositions, medicaments, and pharmaceutical kits that employ the use of boceprevir as a cyp3a4/5 inhibitor to improve the pharmacokinetics of therapeutic compounds metabolized by cytochrome p450 3a4/5 (cyp3a4/5) enzymes.. .
06/12/14
20140161860
Implantable polymeric device for sustained release of buprenorphine
The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time.
06/12/14
20140161766
Tetrameric cytokines with improved biological activity
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety.
06/05/14
20140155560
Nitrogen containing external donor system for propylene polymerization
The present invention discloses new class of nitrogen containing external donor systems. These donor systems are used in titanium supported on magnesium dichloride pro-catalyst system for polymerization of propylene.
06/05/14
20140154697
Apparatus and method for measuring binding kinetics with a resonating sensor
Apparatus and method for detecting a presence of a subject material in a fluid sample using at least one resonating sensor immersible in the fluid sample. Binding kinetics of an interaction of an analyte material present in the fluid sample are measured with the resonating sensor, which has binding sites for the analyte material.
06/05/14
20140151245
Systems and methods of discriminating between a control sample and a test fluid using capacitance
Methods for distinguishing between an aqueous non-blood sample (e.g., a control solution) and a blood sample are provided herein. In one aspect, the method includes using a test strip in which multiple current transients are measured by a meter electrically connected to an electrochemical test strip.
06/05/14
20140151244
Systems and methods of discriminating between a control sample and a test fluid using capacitance
Methods for distinguishing between an aqueous non-blood sample (e.g., a control solution) and a blood sample are provided herein. In one aspect, the method includes using a test strip in which multiple current transients are measured by a meter electrically connected to an electrochemical test strip.
06/05/14
20140151243
Systems and methods of discriminating between a control sample and a test fluid using capacitance
Methods for distinguishing between an aqueous non-blood sample (e.g., a control solution) and a blood sample are provided herein. In one aspect, the method includes using a test strip in which multiple current transients are measured by a meter electrically connected to an electrochemical test strip.


Popular terms: [SEARCH]

Kinetics topics: Medical Device, Polypeptide, Nucleic Acid, Nucleic Acids, Specificity, Surfactant, Enhancement, Scattering, Electrolyte, Conductive Elements, Amplification, Red Blood Cell, Red Blood Cells, Antibodies, Luciferase

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Kinetics for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Kinetics with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.6259

3283

3 - 0 - 72